Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04001088 · ClinicalTrials.gov registry record · Phase 2
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health
A Phase 2 study, sponsored by Lallemand Health Solutions.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT04001088: Completed Phase 2 study, sponsored by Lallemand Health Solutions.
NCT04001088 is a Phase 2 study that has completed, run by Lallemand Health Solutions. The registered enrollment target is 144 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04001088, a Phase 2 study, has completed, sponsored by Lallemand Health Solutions.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in postmenopausal women.
Primary Outcome
Assessed using Menopause Rating Scale (MRS) rating scale. 11 questions on a scale from no complaints (0) to very severe symptoms (4). Subscores are added to create a composite or total score. A higher score indicates a greater severity of menopausal symptoms.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Probiotic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2021-04-23 |
| Phase | Phase 2 |
What the finished NCT04001088 record still lists
NCT04001088 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04001088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04001088 about?
NCT04001088 is a clinical study titled "The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health". This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in postmenopausal women.
What is the current status of trial NCT04001088?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2019-07-29. Estimated completion is 2021-04-23.
What interventions are being tested in trial NCT04001088?
The interventions under investigation include: Placebo (OTHER), Probiotic (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04001088?
This trial is sponsored by Lallemand Health Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04001088's enrollment target sits among peer trials
144 500th of 2000 higher than 1,494 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI